D. Ogston

VENOUS THROMBOSIS FOLLOWING STROKES

Abstract Thirty patients with a recent cerebro- Summaryn vascular accident resulting in a stroke were studied for evidence of leg-vein thrombosis using the 125 I-labelled fibrinogen technique. 60% developed a deep-venous thrombosis, as measured by this technique, in their paralysed leg; 7% had, in addition, a thrombus in the non-paralysed leg.

THE INFLUENCE OF CIGARETTE SMOKING ON THE PLASMA FIBRINOGEN CONCENTRATION

Abstract The plasma concentration of fibrinogen was not altered by smoking one cigarette, but the normal rise in the plasma fibrinogen level with age was accentuated in healthy subjects who smoked 10 or more cigarettes a day.

The effect of clofibrate on components of the fibrinolytic enzyme system

Abstract The administration of clofibrate (2 g/day) resulted in a significant reduction in the serum cholesterol and plasma fibrinogen levels over the 3-month period of study. There was a fall in the a2-macroglobulin level, but no alteration in al-anti-trypsin level, antiplasmin activity, activation inhibitor or plasma fibrinolytic activity.

Platelet Function after the Administration of Chlorpromazine to Human Subjects

Chlorpromazine is known to inhibit platelet function in vitro. The intramuscular injection of 50 mg to human volunteers caused only minor changes in platelet function. There was a small, but significant, reduction in the platelet count, the second phase of the double-wave of adenosine diphosphate-induced aggregation and the rate of 5-hydroxytryptamine-induced aggregation. Patients on high doses of chlorpromazine had no demonstrable abnormality of platelet function. This suggests that chlorpromazine, despite its inhibitory effect on platelet function in vitro, is unlikely to interfere with either haemostasis or thrombogenesis after its administration to man.